Literature DB >> 23440596

Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.

Fei Su1, Bruna R S Correa, Jianhua Luo, Ricardo Z N Vencio, Laura E Pascal, Zhou Wang.   

Abstract

U19/EAF2 is regulated by androgens in the prostate and capable of regulating transcriptional elongation of RNA Pol II via interaction with the ELL family proteins. Inactivation of U19/EAF2 induces tumorigenesis in multiple organs; however the mechanism of U19/EAF2 tumor suppression remains unclear. To elucidate potential mechanisms of U19/EAF2 action, we performed cDNA microarray analysis and identified 164 mRNA transcripts regulated by U19/EAF2 in the mouse ventral prostate. Bioinformatics analysis indicated that U19/EAF2 knockout activates the RAS-BRAF-ERK signaling pathway, which is known to play important roles in carcinogenesis. qPCR verified increased expression of BRAF mRNA, and immunostaining and Western blot analysis demonstrated increased expression of p-ERK at the protein level suggested U19/EAF2 knockout activates this important pathway. These findings indicate that loss of EAF2 up-regulates transcription of RAS cascade genes including Grb2, PI3K, and BRAF, leading to elevated p-ERK levels, which may represent a major functional role of U19/EAF2 in the prostate. Furthermore, these observations suggest that U19/EAF2 is a key player in crosstalk between androgen receptor and the RAS-BRAF-ERK signaling pathway.

Entities:  

Year:  2013        PMID: 23440596      PMCID: PMC3855377          DOI: 10.1007/s12307-013-0132-4

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  55 in total

1.  ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.

Authors:  Wuhan Xiao; Feng Jiang; Zhou Wang
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

2.  Genes regulated by androgen in the rat ventral prostate.

Authors:  Z Wang; R Tufts; R Haleem; X Cai
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.

Authors:  Lance C Bridges; Patricia H Tani; Krista R Hanson; Charles M Roberts; Matthew B Judkins; Ron D Bowditch
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

4.  Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.

Authors:  Marc Colombel; Stéphanie Filleur; Pierick Fournier; Carole Merle; Julien Guglielmi; Aurélie Courtin; Armelle Degeorges; Claire Marie Serre; Raymonde Bouvier; Philippe Clézardin; Florence Cabon
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

Review 5.  Signal transduction in prostate cancer progression.

Authors:  Daniel Gioeli
Journal:  Clin Sci (Lond)       Date:  2005-04       Impact factor: 6.124

6.  Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.

Authors:  C Kwak; R J Jin; C Lee; M S Park; S E Lee
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

7.  Bromodomain 4 activation predicts breast cancer survival.

Authors:  Nigel P S Crawford; Jude Alsarraj; Luanne Lukes; Renard C Walker; Jennifer S Officewala; Howard H Yang; Maxwell P Lee; Keiko Ozato; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

8.  A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

Authors:  William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

Review 9.  Therapeutic strategies for inhibiting oncogenic BRAF signaling.

Authors:  Ensar Halilovic; David B Solit
Journal:  Curr Opin Pharmacol       Date:  2008-08-03       Impact factor: 5.547

10.  Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer.

Authors:  Wuhan Xiao; Qiuheng Zhang; Feng Jiang; Michael Pins; James M Kozlowski; Zhou Wang
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  7 in total

1.  Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.

Authors:  Laura E Pascal; Khalid Z Masoodi; June Liu; Xiaonan Qiu; Qiong Song; Yujuan Wang; Yachen Zang; Tiejun Yang; Yao Wang; Lora H Rigatti; Uma Chandran; Leandro M Colli; Ricardo Z N Vencio; Yi Lu; Jian Zhang; Zhou Wang
Journal:  J Endocrinol       Date:  2017-11       Impact factor: 4.286

2.  FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.

Authors:  Wenhuan Guo; Anne L Keener; Yifeng Jing; Liquan Cai; Junkui Ai; Jian Zhang; A L Fisher; Guohui Fu; Zhou Wang
Journal:  Prostate       Date:  2015-03-23       Impact factor: 4.104

3.  Sequence, structural and functional conservation among the human and fission yeast ELL and EAF transcription elongation factors.

Authors:  Kumari Sweta; Preeti Dabas; Nimisha Sharma
Journal:  Mol Biol Rep       Date:  2021-11-22       Impact factor: 2.316

4.  EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer.

Authors:  Laura E Pascal; Yao Wang; Mingming Zhong; Dan Wang; Anish Bhaswanth Chakka; Zhenyu Yang; Feng Li; Qiong Song; Lora H Rigatti; Srilakshmi Chaparala; Uma Chandran; Anil V Parwani; Zhou Wang
Journal:  Neoplasia       Date:  2018-03-06       Impact factor: 5.715

5.  Effects of ELL-associated factor 2 on ultraviolet radiation-induced cataract formation in mice.

Authors:  Yanhua Jiang; Rongrong Fu; Jiangyue Zhao; Di Wu; Guang Qiao; Ruoxi Li; Jinsong Zhang
Journal:  Mol Med Rep       Date:  2015-09-02       Impact factor: 2.952

6.  Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.

Authors:  Laura E Pascal; Junkui Ai; Khalid Z Masoodi; Yujuan Wang; Dan Wang; Kurtis Eisermann; Lora H Rigatti; Katherine J O'Malley; Hei M Ma; Xinhui Wang; Javid A Dar; Anil V Parwani; Brian W Simons; Michael M Ittman; Luyuan Li; Benjamin J Davies; Zhou Wang
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

7.  EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling.

Authors:  Bo Pang; Xiang-Rong Zheng; Jing-Xia Tian; Tai-Hong Gao; Guang-Yan Gu; Rui Zhang; Yi-Bing Fu; Qi Pang; Xin-Gang Li; Qian Liu
Journal:  Oncotarget       Date:  2016-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.